AOCI at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s AOCI?
- Monte Rosa Therapeutics, Inc. (GLUE) reported AOCI of -$4.75M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s AOCI changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s AOCI decreased by 42.6% year-over-year, from -$3.33M to -$4.75M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s AOCI has grown at a 29.4% compound annual growth rate (CAGR), from -$1.06M to -$3.83M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.